New Triple-Drug attack aims to outsmart Hard-to-Treat colorectal cancer
Disease control
Recruiting now
This study tests a new experimental drug (ABT-301) combined with two existing cancer treatments (tislelizumab and bevacizumab) in people with a specific type of advanced colorectal cancer that has not responded to at least two prior therapies. The goal is to find the safest and m…
Phase: PHASE1, PHASE2 • Sponsor: Anbogen Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 07:32 UTC